Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | Amyloidosis Sessions: Highlights from ISA 2022

Ashutosh Wechalekar and Shaji Kumar • 6 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Antibodies Daratumumab

Welcome to The Amyloidosis Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). This exclusive session a discussion from the 18th Meeting of the International Society of Amyloidosis (ISA) with leading experts Shaji Kumar, MD, Mayo Clinic, Rochester, MN, and Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, University College London, London, UK, who share their highlights in amyloidosis from the meeting.

More from Ashutosh Wechalekar

Advances in the treatment and diagnosis of amyloidosis: what does the future hold?
1:36
Advances in the treatment and diagnosis of amyloidosis: what does the future hold?
Ashutosh Wechalekar • 13 Jun 2025
Treatment strategies for patients with R/R amyloidosis: targeting BCL2 or BCMA
1:34
Treatment strategies for patients with R/R amyloidosis: targeting BCL2 or BCMA
Ashutosh Wechalekar • 13 Jun 2025
Hidden light chain amyloidosis in patients with multiple myeloma
1:45
Hidden light chain amyloidosis in patients with multiple myeloma
Ashutosh Wechalekar • 13 Jun 2025
Results of the Phase III AFFIRM-AL trial of birtamimab in AL amyloidosis
1:12
Results of the Phase III AFFIRM-AL trial of birtamimab in AL amyloidosis
Ashutosh Wechalekar • 14 Jun 2025

More from Shaji Kumar

Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma
3:00
Long-term efficacy and safety of etentamig, a BCMA bispecific antibody, in R/R multiple myeloma
Shaji Kumar • 17 Jun 2025
Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma
2:37
Long-term outcomes from the ENDURANCE trial: VRd versus KRD in newly diagnosed myeloma
Shaji Kumar • 17 Jun 2025
The feasibility of outpatient strategies for treating multiple myeloma with bispecifics and CAR-T
1:57
The feasibility of outpatient strategies for treating multiple myeloma with bispecifics and CAR-T
Shaji Kumar • 17 Jun 2025
RedirecTT-1: the safety and efficacy of talquetamab and teclistamab in R/R multiple myeloma with EMD
5:43
RedirecTT-1: the safety and efficacy of talquetamab and teclistamab in R/R multiple myeloma with EMD
Shaji Kumar • 17 Jun 2025

Related Videos

Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
1:40
Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
Naveen Pemmaraju • 30 May 2026
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
2:20
How the FDA approval of pivekimab sunirine may shape the field of BPDCN & advice for clinicians
Naveen Pemmaraju • 29 May 2026
The importance of alloSCT in improving outcomes for patients with BPDCN
1:40
The importance of alloSCT in improving outcomes for patients with BPDCN
Naveen Pemmaraju • 29 May 2026
First results of LINKER-AL2: linvoseltamab in patients with R/R systemic AL amyloidosis
2:51
First results of LINKER-AL2: linvoseltamab in patients with R/R systemic AL amyloidosis
Hans Lee • 30 May 2026
The content of VJHemOnc is intended for healthcare professionals